Form 4: MariMed CCO Ryan Crandall Receives RSU Grant
Statement of Changes in Beneficial Ownership
MariMed Inc. Chief Commercial Officer Ryan Crandall was granted 131,250 restricted stock units in lieu of a cash bonus.
Summary
- Ryan Crandall, Chief Commercial Officer of MariMed Inc., received a grant of 131,250 restricted stock units (RSUs).
- The grant was issued on April 15, 2026, as a substitute for a portion of his annual cash bonus for the 2025 fiscal year.
- The RSUs will vest in four equal quarterly installments starting July 15, 2026, and concluding April 15, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation that does not signal a change in company performance or strategy.
Positives
- Aligns executive compensation with long-term shareholder interests through equity-based incentives.
- Preserves company cash reserves by utilizing equity in lieu of a cash bonus payment.
Negatives
- Results in potential future dilution for existing shareholders upon the vesting and conversion of the RSUs into common stock.
Risks
- Market volatility could impact the ultimate value of the equity compensation for the executive.
- Retention risk if the executive does not remain with the company through the full vesting period.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on executive compensation structure.
Management Comments
- The RSUs were granted in lieu of cash payment of a portion of the Reporting Person's annual bonus for the fiscal year ended December 31, 2025.
Industry Context
StockSavvy.ai notes that it is common practice in the cannabis sector for companies to manage cash flow by compensating executives with equity, particularly when preserving capital for operational expansion.
Comparison to Industry Standards
- Equity-based compensation is a standard retention tool in the high-growth cannabis industry.
- The use of RSUs in lieu of cash is a common strategy for mid-cap companies to maintain liquidity.
Stakeholder Impact
- Shareholders may experience minor dilution upon the vesting of these units.
Next Steps
- Vesting of the first tranche of RSUs on July 15, 2026.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | End of fiscal year for which the bonus was earned. |
| 2026-04-15 | Date of RSU grant. |
| 2026-04-16 | Date of filing. |
| 2026-07-15 | First vesting date. |
| 2026-10-15 | Second vesting date. |
| 2027-01-15 | Third vesting date. |
| 2027-04-15 | Final vesting date. |
Keywords
MariMed, MRMD, Insider Trading, Executive Compensation, Form 4, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.